Skip to content

Prestige Consumer Healthcare PBH Treasury stock, shares (in shares)

Treasury stock, shares (in shares) at other companies

Kenvue logo
KenvueKVUE
Cardinal Health logo
Cardinal HealthCAH
Abbott logo
AbbottABT
Clorox logo
CloroxCLX
Coty logo
CotyCOTY
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH

Other financials

Income statement

See full
Revenue$281.6M-5.0%
Gross profit$146.3M-13.9%
Operating income$75.5M-14.6%
Net income$53.9M+7.6%
EPS (diluted)$1.13+11.9%

Balance sheet

See full
Cash & equivalents$63.9M-34.8%
Total debt$1.0B-0.2%
Total equity$1.9B+2.9%
Total assets$3.5B+2.7%

Cash flow

See full
Operating cash flow$42.8M-30.7%
CapEx$5.2M+49.8%
Free cash flow$37.6M-35.5%

Valuation

See full
Market cap$2.24B-34.1%

Profitability

See full
Gross margin54.7%-1.1pp
Operating margin28.4%-1.2pp
Net margin17.5%-1.4pp
FCF margin22.6%+1.3pp

Returns & leverage

See full
Return on equity10.2%-2.1pp
Debt / equity0.6×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonShares.

The official record: Prestige Consumer Healthcare’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prestige Consumer Healthcare's treasury stock, shares (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prestige Consumer Healthcare's treasury stock, shares (in shares)?
Prestige Consumer Healthcare (PBH) reported treasury stock, shares (in shares) of $8.88M in Q4 2025.
How has Prestige Consumer Healthcare's treasury stock, shares (in shares) changed year-over-year?
Prestige Consumer Healthcare's treasury stock, shares (in shares) increased by 39.5% year-over-year, from $6.36M to $8.88M.
What is the long-term trend for Prestige Consumer Healthcare's treasury stock, shares (in shares)?
Over 3 years (2022 to 2025), Prestige Consumer Healthcare's treasury stock, shares (in shares) has grown at a 16.1% compound annual growth rate (CAGR), from $4.15M to $6.5M.